Trials / Completed
CompletedNCT04882449
Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events
Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF1
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 329 (actual)
- Sponsor
- Bodyport Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.
Detailed description
The overarching goal of this prospective, multicenter study is to utilize data from the Bodyport Cardiac Scale to develop an index that allows for the early detection of worsening heart failure (HF). The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF. The SCALE-HF program will consist of multiple phases. For SCALE-HF 1, patients will be prospectively enrolled and utilize the Bodyport Cardiac Scale on a daily basis. Patients and clinicians will be blinded to the results other than data readily available from other devices such as body weight. There will be no attempt to influence clinical practice. Patients will be followed remotely for suspected clinical events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Bodyport Cardiac Scale | The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF. |
Timeline
- Start date
- 2021-07-08
- Primary completion
- 2023-04-30
- Completion
- 2023-07-31
- First posted
- 2021-05-12
- Last updated
- 2025-02-10
- Results posted
- 2025-02-10
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04882449. Inclusion in this directory is not an endorsement.